Vifor, Angion organ damage drug fails phase 3 kidney transplant studyVifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this Share XVifor, Angion organ damage drug fails phase 3 kidney transplant studyhttps://pharmaphorum.com/news/vifor-angion-organ-damage-drug-fails-phase-3-kidney-transplant-study/
